RYVIX | VENAX | RYVIX / VENAX | |
Total Expense Ratio | 1.42 | 0.09 | 1,578% |
Annual Report Gross Expense Ratio | 1.45 | 0.09 | 1,611% |
Fund Existence | 27 years | 21 years | - |
Gain YTD | -21.245 | -3.553 | 598% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 2500 | 100000 | 3% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 4.3M | 8.09B | 0% |
Annual Yield % from dividends | 0.00 | 3.50 | - |
Returns for 1 year | -33.34 | -10.42 | 320% |
Returns for 3 years | -15.98 | 4.43 | -361% |
Returns for 5 years | 80.93 | 132.02 | 61% |
Returns for 10 years | -72.22 | 4.26 | -1,695% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
SGGDX | 35.69 | 0.69 | +1.97% |
First Eagle Gold A | |||
BRKUX | 15.08 | 0.03 | +0.20% |
MFS Blended Research Em Mkts Eq R4 | |||
SFCWX | 69.24 | -1.13 | -1.61% |
American Funds SMALLCAP World F3 | |||
RTDAX | 15.04 | -0.26 | -1.70% |
Russell Inv Multifactor US Equity A | |||
EPLPX | 21.25 | -0.37 | -1.71% |
NYLI Epoch U.S. Equity Yield Class A |